Withdrawal of hormone replacement therapy might affect multigene signature results in early luminal breast cancer.
Department of Gynaecology and Obstetrics; Multidisciplinary Breast Center; Department of Oncology, KU Leuven-University of Leuven, University Hospitals Leuven, Leuven; patrick.neven@uzleuven.be.
P
P
Neven
Department of Oncology, KU Leuven-University of Leuven, University Hospitals Leuven, Leuven;
L
L
Jongen
Department of Oncology, KU Leuven-University of Leuven, University Hospitals Leuven, Leuven;
K
K
Van Asten
Department of Gynaecology and Obstetrics; Multidisciplinary Breast Center; Department of Oncology, KU Leuven-University of Leuven, University Hospitals Leuven, Leuven;
P
P
Berteloot
Multidisciplinary Breast Center; Department of Imaging and Pathology, Laboratory of Translational Cell & Tissue Research, KU Leuven-University of Leuven, Leuven; Departments of Pathology;
G
G
Floris
Multidisciplinary Breast Center; Department of Oncology, KU Leuven-University of Leuven, University Hospitals Leuven, Leuven; General Medical Oncology, KU Leuven-University of Leuven, University Hospitals Leuven, Leuven, Belgium.
H
H
Wildiers
D062005:Biopsy, Large-Core Needle; D001943:Breast Neoplasms / Q000235:genetics* / Q000473:pathology*; D005260:Female; D020249:Hormone Replacement Therapy / Q000009:adverse effects*; D006801:Humans; D059467:Transcriptome / Q000187:drug effects*